[go: up one dir, main page]

WO2022129210A3 - Inhibition de protéase virale - Google Patents

Inhibition de protéase virale Download PDF

Info

Publication number
WO2022129210A3
WO2022129210A3 PCT/EP2021/085966 EP2021085966W WO2022129210A3 WO 2022129210 A3 WO2022129210 A3 WO 2022129210A3 EP 2021085966 W EP2021085966 W EP 2021085966W WO 2022129210 A3 WO2022129210 A3 WO 2022129210A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibition
virus protease
formula
composition
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2021/085966
Other languages
English (en)
Other versions
WO2022129210A2 (fr
Inventor
Grzegorz Maria POPOWICZ
Michael Sattler
Kamyar HADIAN
Oliver Plettenburg
Andre MOURAO
Karl Kenji SCHORPP
Valeria NAPOLITANO
Krzysztof Pyrc
Katarzyna Owczarek
Agnieszka DABROWSKA
Pawel BOTWINA
Aleksandra MILEWSKA
Tony FROEHLICH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Uniwersytet Jagiellonski
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Uniwersytet Jagiellonski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from LU102310A external-priority patent/LU102310B1/en
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH, Uniwersytet Jagiellonski filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Publication of WO2022129210A2 publication Critical patent/WO2022129210A2/fr
Publication of WO2022129210A3 publication Critical patent/WO2022129210A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B15/00—Acridine dyes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition comprenant au moins un composé selon la formule (I) ainsi qu'une composition comprenant au moins un composé selon la formule (I) et/ou des dimères de composés selon la formule (I) en particulier pour une utilisation dans le traitement de maladies provoquées par des bétacoronavirus, la leishmaniose et la trypanosomiase.
PCT/EP2021/085966 2020-12-15 2021-12-15 Inhibition de protéase virale Ceased WO2022129210A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20214108 2020-12-15
EP20214108.1 2020-12-15
LU102310A LU102310B1 (en) 2020-12-17 2020-12-17 Inhibition of virus protease
LULU102310 2020-12-17

Publications (2)

Publication Number Publication Date
WO2022129210A2 WO2022129210A2 (fr) 2022-06-23
WO2022129210A3 true WO2022129210A3 (fr) 2022-07-28

Family

ID=79287793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/085966 Ceased WO2022129210A2 (fr) 2020-12-15 2021-12-15 Inhibition de protéase virale

Country Status (1)

Country Link
WO (1) WO2022129210A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120118126B (zh) * 2025-05-13 2025-08-26 上海健康医学院 咔唑金属配合物及其制备方法和在制备抗新型冠状病毒的药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711527A1 (fr) * 1993-10-22 1995-05-05 Richard Laboratoire M Utilisation de l'acriflavine comme agent anti HIV.
US20060211029A1 (en) * 2005-03-17 2006-09-21 Fei Mao Methods of using dyes in association with nucleic acid staining or detection and associated technology
WO2007011834A2 (fr) * 2005-07-15 2007-01-25 The Regents Of The University Of California Composes et procede pour diagnostiquer et traiter les maladies associees aux amyloides
US7544712B1 (en) * 2003-05-28 2009-06-09 National Health Research Insitutes Treatment of coronavirus infection
CN106471067A (zh) * 2014-04-01 2017-03-01 霍华德休斯医学研究所 氮杂环丁烷取代的荧光化合物
KR20170122344A (ko) * 2016-04-26 2017-11-06 에스에프씨 주식회사 아크리딘계 화합물, 이를 포함하는 생체분자 표지용 염료, 키트 및 조영제 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711527A1 (fr) * 1993-10-22 1995-05-05 Richard Laboratoire M Utilisation de l'acriflavine comme agent anti HIV.
US7544712B1 (en) * 2003-05-28 2009-06-09 National Health Research Insitutes Treatment of coronavirus infection
US20060211029A1 (en) * 2005-03-17 2006-09-21 Fei Mao Methods of using dyes in association with nucleic acid staining or detection and associated technology
WO2007011834A2 (fr) * 2005-07-15 2007-01-25 The Regents Of The University Of California Composes et procede pour diagnostiquer et traiter les maladies associees aux amyloides
CN106471067A (zh) * 2014-04-01 2017-03-01 霍华德休斯医学研究所 氮杂环丁烷取代的荧光化合物
KR20170122344A (ko) * 2016-04-26 2017-11-06 에스에프씨 주식회사 아크리딘계 화합물, 이를 포함하는 생체분자 표지용 염료, 키트 및 조영제 조성물

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BENCHABANE Y ET AL: "Photo-inducible cytotoxic and clastogenic activities of 3,6-di-substituted acridines obtained by acylation of proflavine", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 44, no. 6, 1 June 2009 (2009-06-01), pages 2459 - 2467, XP026049343, ISSN: 0223-5234, [retrieved on 20090120], DOI: 10.1016/J.EJMECH.2009.01.010 *
CAGNO VALERIA ET AL: "Methylene Blue has a potent antiviral activity against SARS-CoV-2 in the absence of UV-activation in vitro", BIORXIV, 14 August 2020 (2020-08-14), XP055818844, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.08.14.251090v1.full.pdf> [retrieved on 20210628], DOI: 10.1101/2020.08.14.251090 *
CHEN CHIING-CHANG ET AL: "Chemical Oxidative Degradation of Acridine Orange Dye in Aqueous Solution by Fenton's Reagent", JOURNAL OF THE CHINESE CHEMICAL SOCIETY., vol. 56, no. 6, 1 December 2009 (2009-12-01), CHINA, pages 1147 - 1155, XP055898909, ISSN: 0009-4536, Retrieved from the Internet <URL:http://dx.doi.org/10.1002/jccs.200900165> DOI: 10.1002/jccs.200900165 *
DI GIORGIO ET AL: "Synthesis and antileishmanial activity of 6-mono-substituted and 3,6-di-substituted acridines obtained by acylation of proflavine", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 42, no. 10, 13 October 2007 (2007-10-13), pages 1277 - 1284, XP022297750, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2007.02.010 *
FIRTH W J ET AL: "IDENTIFICATION OF AN ACRIDINE PHOTOAFFINITY PROBE FOR TRYPANOCIDAL ACTION", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 27, no. 7, 1 July 1984 (1984-07-01), pages 865 - 870, XP000604726, ISSN: 0022-2623, DOI: 10.1021/JM00373A010 *
HARRISON R J ET AL: "Evaluation of by disubstituted acridone derivatives as telomerase inhibitors: the importance of G-quadruplex binding", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 14, no. 23, 6 December 2004 (2004-12-06), pages 5845 - 5849, XP004611132, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2004.09.037 *
KAIFU GAO ET AL: "Repositioning of 8565 existing drugs for COVID-19", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 20 May 2020 (2020-05-20), XP081675612 *
KUBOTA YUKIO ET AL: "Equilibrium Dialysis Studies of the DNA-Acridine Complexes", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 49, no. 9, 1 September 1976 (1976-09-01), JP, pages 2424 - 2426, XP055898944, ISSN: 0009-2673, DOI: 10.1246/bcsj.49.2424 *
LISHENG CAI ET AL: "Radioligand Development for PET Imaging of β-Amyloid (Aβ)-Current Status", CURRENT MEDICINAL CHEMISTRY, vol. 14, no. 1, 1 January 2007 (2007-01-01), NL, pages 19 - 52, XP055252033, ISSN: 0929-8673, DOI: 10.2174/092986707779313471 *
LOPEZ-LEON SANDRA ET AL: "More than 50 long-term effects of COVID-19: a systematic review and meta-analysis", vol. 11, no. 1, 9 August 2021 (2021-08-09), XP055839326, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-021-95565-8.pdf> DOI: 10.1038/s41598-021-95565-8 *
MESHNICK ET AL: "Recent studies on inhibitors of macromolecular synthesis and function in trypanosomes", PHARMACOLOGY & THERAPEUTICS, ELSEVIER, GB, vol. 25, no. 2, 1 January 1984 (1984-01-01), pages 239 - 254, XP025527243, ISSN: 0163-7258, [retrieved on 19840101], DOI: 10.1016/0163-7258(84)90045-7 *
MURAKAMI KIYOFUMI ET AL: "Equilibrium and Kinetic Studies of the Dimerization of Acridine Orange and Its 10-Alkyl Derivatives", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 59, no. 11, 1 November 1986 (1986-11-01), JP, pages 3393 - 3397, XP055898937, ISSN: 0009-2673, DOI: 10.1246/bcsj.59.3393 *
NAPOLITANO VALERIA ET AL: "Acriflavine, a clinically aproved drug, inhibits SARS-CoV-2 and other betacoronaviruses", BIORXIV, 21 March 2021 (2021-03-21), pages 1 - 24, XP055837869, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2021.03.20.436259v1.full.pdf> [retrieved on 20210906], DOI: 10.1101/2021.03.20.436259 *

Also Published As

Publication number Publication date
WO2022129210A2 (fr) 2022-06-23

Similar Documents

Publication Publication Date Title
MX2023014307A (es) Inhibidores de proteasa como antivirales.
MY209340A (en) Egfr inhibitor for the treatment of cancer
ZA202308854B (en) A pan-kras inhibitor compound
ZA202213152B (en) Novel acid secretion inhibitor and use thereof
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
MX2025003398A (es) Nuevo compuesto tetraheterociclico
ZA202310783B (en) A pan-kras inhibitor compound
ZA202310514B (en) A pan-kras inhibitor compound
AU2020231934A8 (en) Compounds useful in HIV therapy
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
WO2020104648A3 (fr) INHIBITEUR DE TGFβ ET PROMÉDICAMENTS
CU20210088A7 (es) Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
WO2023054732A3 (fr) Produit pharmaceutique pour le traitement d&#39;une infection au nouveau coronavirus
MX2022009967A (es) Compuestos para el tratamiento de la infeccion por coronavirus.
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
MX2025012370A (es) Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta
MX2023002525A (es) Nuevos compuestos.
MX2021002188A (es) Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende.
MX2022010957A (es) Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn.
AU2020353055A8 (en) Antiviral pyrazolopyridinone compounds
BRPI0512970A (pt) prodrogas de inibidores da hiv protease
WO2022129210A3 (fr) Inhibition de protéase virale
MX2022013692A (es) Compuesto que tiene actividad inhibidora de desmetilasa 5 (kdm5) y uso farmaceutico del mismo.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21839911

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21839911

Country of ref document: EP

Kind code of ref document: A2